|
⚲
|
| Keyboard |
| Schenkein David P
✚
|
|
|---|---|
| CIK # | 0001578200 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 3 | [0001578200] | |
| 4 | [0001578200] |
| Form 3/4/5 Subject | 2011 - 2026 |
|---|---|
| Prime Medicine Inc | |
| Schenkein David P | |
| Denali Therapeutics Inc | |
| Regeneron Pharmaceuticals Inc | |
| Agios Pharmaceuticals Inc | |
| bluebird bio Inc | |
| Foundation Medicine Inc |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Regeneron Pharmaceuticals Inc REGN
Non-Qualified Stock Option (right to buy) · derivative
|
2026-01-02 | Grant | 1,962 | $0.00 | |
|
Regeneron Pharmaceuticals Inc REGN
Common Stock
|
2026-01-02 | Grant | 155 | $0.00 | |
|
Prime Medicine Inc PRME
Stock Option (right to buy) · derivative
|
2025-08-01 | Grant | 39,062 | ||
|
Prime Medicine Inc PRME
Stock Option (right to buy) · derivative
|
2025-08-01 | Grant | 45,000 | ||
|
Prime Medicine Inc PRME
Stock Option (right to buy) · derivative
|
2025-08-01 | Disposed to issuer | 39,062 | ||
|
Prime Medicine Inc PRME
Stock Option (right to buy) · derivative
|
2025-08-01 | Disposed to issuer | 45,000 | ||
|
Prime Medicine Inc PRME
Stock Option (right to buy) · derivative
|
2025-06-04 | Grant | 55,000 | $0.00 | |
|
Denali Therapeutics Inc DNLI
Common Stock
|
2025-06-03 | Grant | 6,037 | $0.00 | |
|
Denali Therapeutics Inc DNLI
Stock Option (right to buy) · derivative
|
2025-06-03 | Grant | 18,111 | $0.00 | |
|
Regeneron Pharmaceuticals Inc REGN
Common Stock
|
2025-01-02 | Grant | 166 | $0.00 | |
|
Regeneron Pharmaceuticals Inc REGN
Non-Qualified Stock Option (right to buy) · derivative
|
2025-01-02 | Grant | 1,958 | $0.00 | |
|
Denali Therapeutics Inc DNLI
Common Stock
|
2024-11-11 | Option exercise | 47,165 | $18.00 | 848,970 |
|
Denali Therapeutics Inc DNLI
Common Stock
|
2024-11-11 | Sell | 27,129 | $32.09 | 870,570 |
|
Denali Therapeutics Inc DNLI
Common Stock
|
2024-11-11 | Sell | 32,312 | $32.87 | 1,062,095 |
|
Denali Therapeutics Inc DNLI
Stock Option (right to buy) · derivative
|
2024-11-11 | Option exercise | 47,165 | $0.00 | |
|
Agios Pharmaceuticals Inc AGIO
Restricted stock units · derivative
|
2024-06-20 | Grant | 2,120 | $0.00 | |
|
Agios Pharmaceuticals Inc AGIO
Stock options (right to buy) · derivative
|
2024-06-20 | Grant | 11,774 | $0.00 | |
|
Agios Pharmaceuticals Inc AGIO
Restricted stock units · derivative
|
2024-06-13 | Option exercise | 3,388 | $0.00 | |
|
Agios Pharmaceuticals Inc AGIO
Common stock
|
2024-06-13 | Option exercise | 3,388 | $0.00 | |
|
Prime Medicine Inc PRME
Stock Option (right to buy) · derivative
|
2024-06-12 | Grant | 45,000 | $0.00 | |
| showing 20 of 200 most recent transactions | |||||